MétaCan
Menu
Back to cohort
Record W4386819540 · doi:10.1093/bjd/ljad281

Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial

2023· article· en· W4386819540 on OpenAlexaff
Anna Rosala‐Hallas, Ashley P Jones, Paula Beattie, Susannah Baron, Fiona Browne, Sara Brown, J. E. Gach, Danielle Greenblatt, Ross Hearn, Eva Hilger, Ben Esdaile, Michael J. Cork, Emma Howard, Marie‐Louise Lovgren, Suzannah August, Farhiya Ashoor, Paula Williamson, Tess McPherson, Donal O’Kane, Jane Ravenscroft, Lindsay Shaw, Manish D. Sinha, Catherine Spowart, Leonie S. Taams, Bjorn Thomas, Mandy Wan, Tracey Sach, Alan D. Irvine, Alison Layton, Tim Burton, Michael Grainge, Michael J. Arden-Jones, Saskia King, Michael R. Perkin, Alain Taı̈eb, Anthony D. Ormerod, R.J.G. Chalmers, Xinxue Liu, Amina Ahmed, Amy Holton, Hannah D. Mason, Charlotte Walker, Carsten Flohr, Emma Howard, Caroline Allen, Robert Hearn, Susannah Hoey, Rachael Jarret, Catherine Jury, Charlie Mitchell, Ruth Murphy, Graham S. Ogg, Alice Plant, Louise Newell, Jothsana Srinivasan, Emma Wedgeworth

Bibliographic record

VenueBritish Journal of Dermatology · 2023
Typearticle
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsTrinity College
FundersBritish Association of DermatologistsNational Institute for Health and Care ResearchNational Institutes of HealthMedical Research CouncilBarts CharityQueen Mary University of London
KeywordsMedicineEczema Area and Severity IndexSCORADAtopic dermatitisRandomized controlled trialCiclosporinMethotrexateInternal medicineQuality of life (healthcare)PopulationAdverse effectClinical trialDermatology Life Quality IndexPediatricsDermatologyTransplantationDisease

Abstract

fetched live from OpenAlex

BACKGROUND: Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust randomized controlled trial (RCT) evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower-resource settings. OBJECTIVES: To compare the safety and efficacy of ciclosporin (CyA) with methotrexate (MTX) in CYP with severe AD in the TREatment of severe Atopic Eczema Trial (TREAT) trial. METHODS: We conducted a parallel group assessor-blinded RCT in 13 UK and Irish centres. Eligible participants aged 2-16 years and unresponsive to potent topical treatment were randomized to either oral CyA (4 mg kg-1 daily) or MTX (0.4 mg kg-1 weekly) for 36 weeks and followed-up for 24 weeks. Co-primary outcomes were change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to first significant flare (relapse) after treatment cessation. Secondary outcomes included change in quality of life (QoL) from baseline to 60 weeks; number of participant-reported flares following treatment cessation; proportion of participants achieving ≥ 50% improvement in Eczema Area and Severity Index (EASI 50) and ≥ 75% improvement in EASI (EASI 75); and stratification of outcomes by filaggrin status. RESULTS: In total, 103 participants were randomized (May 2016-February 2019): 52 to CyA and 51 to MTX. CyA showed greater improvement in disease severity by 12 weeks [mean difference in o-SCORAD -5.69, 97.5% confidence interval (CI) -10.81 to -0.57 (P = 0.01)]. More participants achieved ≥ 50% improvement in o-SCORAD (o-SCORAD 50) at 12 weeks in the CyA arm vs. the MTX arm [odds ratio (OR) 2.60, 95% CI 1.23-5.49; P = 0.01]. By 60 weeks MTX was superior (OR 0.33, 95% CI 0.13-0.85; P = 0.02), a trend also seen for ≥ 75% improvement in o-SCORAD (o-SCORAD 75), EASI 50 and EASI 75. Participant-reported flares post-treatment were higher in the CyA arm (OR 3.22, 95% CI 0.42-6.01; P = 0.02). QoL improved with both treatments and was sustained after treatment cessation. Filaggrin status did not affect outcomes. The frequency of adverse events (AEs) was comparable between both treatments. Five (10%) participants on CyA and seven (14%) on MTX experienced a serious AE. CONCLUSIONS: Both CyA and MTX proved effective in CYP with severe AD over 36 weeks. Participants who received CyA showed a more rapid response to treatment, while MTX induced more sustained disease control after discontinuation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.145
Threshold uncertainty score0.505

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.349
Teacher spread0.313 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations43
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of DermatologySame topicDermatology and Skin DiseasesFrench-language works237,207